Comparison of Mycoplasma hyopneumoniae and porcine circovirus 2 commercial vaccines efficacy when applied separate or combined under experimental conditions

• Published in: Porcine Health Management. Vol. 6; no. 1; p. 11
• Main Authors: Sibila, M, Guevara, G, Cuadrado, R, Pleguezuelos, P, Pérez, D, Pérez de Rozas, A, Huerta, E, Llorens, A, Valero, O, Pérez, M, López, C, Krejci, R, Segalés, J
• Format: Journal Article
• Language: English
• Published: England BioMed Central 04.05.2020; BMC
• Subjects: Hogs; Immunization; Infections; Mortality; Mycoplasma hyopneumoniae; Pathogens; Pneumonia; Porcine circovirus 2; Ready-to-mix; Ready-to-use; Vaccine; Vaccines; Porcine circovirus 2; Vaccine; Mycoplasma hyopneumoniae; Ready-to-use; Ready-to-mix
• ISSN: 2055-5660; 2055-5660
• DOI: 10.1186/s40813-020-00148-0

(Mhyo) and (PCV-2) are two of the most significant infectious agents causing economic losses in the weaning to slaughter period. Due to their similar vaccination age, the objective of this study was to assess the efficacy of two already existing Mhyo (Hyogen®) and PCV-2 (Circovac®) vaccines when administered separately or combined (RTM) by means of Mhyo or PCV-2 experimental challenges. Seven groups of animals were included in the study, being three of them challenged with PCV-2, three with Mhyo and one composed of non-challenged, non-vaccinated pigs. Within each experimental challenge, non-vaccinated (NV) groups were compared with double vaccinated groups using the commercial products separated (VS) or combined (VC). Both vaccinated groups showed significant differences for most parameters measured regarding PCV-2 (serology, percentage of infected animals and viral load in tissues) and Mhyo (serology and gross lesions) when compared to NV groups. VS and VC offered similar results, being only significantly different the PCV-2 antibody values at different time points (higher in the VS group) of the study, although not at the termination day (21 days post-PCV-2 inoculation). The present study expands the knowledge on the possibility of using two separate Mhyo and PCV-2 commercial vaccines as a RTM product, which offered equivalent virological, immunological and pathological outcomes as compared to these vaccines when used by separate.